Alice S. Mims

Azacitidine, Venetoclax, and Revumenib for Newly Diagnosed <i>NPM1</i> -Mutated or <i>KMT2A</i> -Rearranged AML

Deconvoluting clonal and cellular architecture in IDH-mutant acute myeloid leukemia

Olutasidenib in combination with azacitidine induces durable complete remissions in patients with relapsed or refractory mIDH1 acute myeloid leukemia: a multicohort open-label phase 1/2 trial

Molecular characterization of newly diagnosed acute myeloid leukemia patients aged 60 years or older: a report from the Beat AML clinical trial

Multi-dimensional analysis of adult acute myeloid leukemia cross-continents reveals age-associated trends in mutational landscape and treatment outcomes (Acute Myeloid Leukemia Cooperative Group &amp; Alliance for Clinical Trials in Oncology)

Revumenib in combination with intensive induction and consolidation for newly diagnosed patients with NPM1-mutated or KMT2A-rearranged Acute Myeloid Leukemia: Preliminary results from the Phase 1b etctn 10596 study

Beat-AML 2024 ELN–refined risk stratification for older adults with newly diagnosed AML given lower-intensity therapy

Multiomic profiling identifies predictors of survival in African American patients with acute myeloid leukemia

Olutasidenib in post-venetoclax patients with mutant isocitrate dehydrogenase 1 (m <i>IDH1</i> ) acute myeloid leukemia (AML)

Olutasidenib demonstrates significant clinical activity in mutated <i>IDH1</i> acute myeloid leukaemia arising from a prior myeloproliferative neoplasm

Acute Myeloid Leukemia, Version 3.2023, NCCN Clinical Practice Guidelines in Oncology

Outcome prediction by the 2022 European LeukemiaNet genetic-risk classification for adults with acute myeloid leukemia: an Alliance study

Chemotherapy-free treatment with inotuzumab ozogamicin and blinatumomab for older adults with newly diagnosed, Ph-negative, CD22-positive, B-cell acute lymphoblastic leukemia: Alliance A041703.

Phase 1 study of vibecotamab identifies an optimized dose for treatment of relapsed/refractory acute myeloid leukemia

Sex-associated differences in frequencies and prognostic impact of recurrent genetic alterations in adult acute myeloid leukemia (Alliance, AMLCG)

Entospletinib with decitabine in acute myeloid leukemia with mutant <i>TP53</i> or complex karyotype: A phase 2 substudy of the Beat AML Master Trial

A study to assess the efficacy of enasidenib and risk-adapted addition of azacitidine in newly diagnosed <i>IDH2</i>-mutant AML

Standardising acute myeloid leukaemia classification systems: a perspective from a panel of international experts

Phase 1 study of selinexor in combination with salvage chemotherapy in Adults with relapsed or refractory Acute myeloid leukemia

Association of social deprivation with survival in younger adult patients with AML: an Alliance study

North American Blastic Plasmacytoid Dendritic Cell Neoplasm Consortium: position on standards of care and areas of need

High early death rates, treatment resistance, and short survival of Black adolescents and young adults with AML

Updated Results from a Phase 1 Study of APVO436, a Novel Bispecific Anti-CD123 x Anti-CD3 Adaptir™ Molecule, in Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome

Disabling Uncompetitive Inhibition of Oncogenic IDH Mutations Drives Acquired Resistance

Pevonedistat with azacitidine in older patients with <i>TP53</i>-mutated AML: a phase 2 study with laboratory correlates

NCCN Guidelines Insights: Acute Myeloid Leukemia, Version 2.2021

A Clinical Phase 1B Study of the CD3xCD123 Bispecific Antibody APVO436 in Patients with Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome

Molecular, clinical, and prognostic implications of <i>PTPN11</i> mutations in acute myeloid leukemia

Ivosidenib or enasidenib combined with intensive chemotherapy in patients with newly diagnosed AML: a phase 1 study

Molecular mechanisms mediating relapse following ivosidenib monotherapy in IDH1-mutant relapsed or refractory AML